Viyash Scientific Unit Executes SPA for BioForLife Italia Acquisition

HYDERABAD, India — Integrated pharmaceutical company Viyash Scientific Limited announced on July 21, 2026, that its step-down wholly owned Irish subsidiary, Alivira Animal Health Limited, has executed a definitive Sale and Purchase Agreement (SPA) to acquire 100% of Milan-based BioForLife Italia S.r.l.. The total transaction value remains pegged at approximately €16.976 million (around ₹188 crore), subject to net financial position adjustments. The updated terms formally revise the deferred consideration framework, linking the retained payout to specific contractual-continuation conditions. The strategic acquisition accelerates Viyash's expansion into Europe’s companion animal healthcare market.

Transaction Valuation and Revised Deferred Structure

According to regulatory disclosures submitted under SEBI Listing Regulations, the base aggregate consideration under the executed SPA comprises an upfront payment of €15.0 million at closing, alongside approximately €1.976 million held as retained or deferred consideration.

In continuation of the preliminary binding agreement signed in June 2026, the final SPA executed on July 21, 2026, explicitly revises the mechanism governing the retained €1.976 million. The payout is now tied directly to specified contractual-continuation conditions, safeguarding post-acquisition commercial relationships and operational stability.

Market Positioning and Strategic Rationale

BioForLife Italia specializes in the development, commercialization, and distribution of pet care products, including veterinary medicines, nutraceuticals, diagnostic kits, and specialized products in dermatology and ophthalmology. The Milan-based firm generated sales of approximately €9.0 million in calendar year 2025, up from €8.3 million in 2024 and €7.1 million in 2023.

The transaction provides Viyash Scientific and Alivira with an established commercial footprint in Italy—Europe’s fifth-largest animal health market—where BioForLife’s sales network caters to over 80% of all veterinary clinics. Beyond local market distribution, Viyash plans to leverage BioForLife’s commercial reach to launch Alivira's generic companion animal pipeline across Europe, Asia, and Latin America.

The completion of the acquisition remains subject to standard closing conditions, including obtaining mandatory Italian foreign direct investment (FDI) and "Golden Power" regulatory clearances.

Official Sources Section

The acquisition details and revised transaction mechanics were communicated via statutory disclosures filed with Indian stock exchanges:

• National Stock Exchange of India (NSE)

• BSE Limited

• Viyash Scientific Investor Relations

Quote Section

"According to officials, the execution of the definitive Sale and Purchase Agreement with a contract-linked deferred consideration mechanism protects shareholder value while establishing an operational platform in Europe's growing companion animal healthcare sector."

Why It Matters

The acquisition establishes an immediate commercial presence for Viyash Scientific in Western Europe’s pet care sector. For the global animal health market, linking part of the acquisition consideration to contractual continuity ensures operational stability across veterinary distribution networks. For investors, the transaction enhances revenue diversification by tapping into high-margin companion animal products across international geographies.

Key Facts at a Glance

• Acquisition Target: 100% stake in Milan-based BioForLife Italia S.r.l.

• Total Valuation: Base consideration of €16.976 million (~₹188 crore).

• Payment Terms: €15.0 million upfront payment at closing; ~€1.976 million in deferred consideration.

• Revised Mechanism: Deferred portion linked to specific contractual-continuation terms.

• Regulatory Approvals: Pending Italian FDI / "Golden Power" clearance.

Frequently Asked Questions (FAQ)

What is the total deal value for BioForLife Italia?

The total base consideration under the SPA is approximately €16.976 million (around ₹188 crore), subject to net financial position adjustments.

How is the payment structured between upfront and deferred components?

The deal involves an upfront cash payment of €15.0 million upon closing, with approximately €1.976 million retained as deferred consideration.

What change was made to the deferred consideration mechanism?

The final SPA revised the deferred consideration mechanism to link the ~€1.976 million payout directly to specified contractual-continuation conditions.

What regulatory clearances are required before closing?

The transaction is subject to fulfillment of standard conditions precedent, including clearance under Italy's Golden Power / Foreign Direct Investment (FDI) laws.

Source: Official regulatory disclosures filed by Viyash Scientific Limited with the National Stock Exchange of India (NSE) and BSE Limited.